Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma Review uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Liver Neoplasms
  • Sirolimus

abstract

  • The outcome of this discussion is summarised here. Guidance for management of these adverse events is provided. Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit.

publication date

  • June 2011

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2011.02.014

PubMed ID

  • 21481584

Additional Document Info

start page

  • 1287

end page

  • 98

volume

  • 47

number

  • 9